An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease

Trial Profile

An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Prasugrel (Primary)
  • Indications Sickle cell anaemia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms Crescent
  • Sponsors Eli Lilly
  • Most Recent Events

    • 15 Aug 2014 New trial record
    • 12 Dec 2012
    • 23 Jan 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top